Huakang Biomedical Holdings (8622) Stock Overview
An investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
8622 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Huakang Biomedical Holdings Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.49 |
| 52 Week High | HK$0.75 |
| 52 Week Low | HK$0.12 |
| Beta | 0.69 |
| 1 Month Change | 24.05% |
| 3 Month Change | 28.95% |
| 1 Year Change | 141.38% |
| 3 Year Change | 153.89% |
| 5 Year Change | 390.00% |
| Change since IPO | 4.26% |
Recent News & Updates
Shareholder Returns
| 8622 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -30.0% | -0.8% | -0.9% |
| 1Y | 141.4% | 58.8% | 29.8% |
Return vs Industry: 8622 exceeded the Hong Kong Medical Equipment industry which returned 58.8% over the past year.
Return vs Market: 8622 exceeded the Hong Kong Market which returned 29.8% over the past year.
Price Volatility
| 8622 volatility | |
|---|---|
| 8622 Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 8622's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8622's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 98 | Chunguang Zhang | www.huakangbiomedical.com |
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors.
Huakang Biomedical Holdings Company Limited Fundamentals Summary
| 8622 fundamental statistics | |
|---|---|
| Market cap | HK$245.23m |
| Earnings (TTM) | -HK$5.18m |
| Revenue (TTM) | HK$28.14m |
Is 8622 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8622 income statement (TTM) | |
|---|---|
| Revenue | CN¥25.77m |
| Cost of Revenue | CN¥8.27m |
| Gross Profit | CN¥17.50m |
| Other Expenses | CN¥22.25m |
| Earnings | -CN¥4.75m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0095 |
| Gross Margin | 67.90% |
| Net Profit Margin | -18.42% |
| Debt/Equity Ratio | 5.4% |
How did 8622 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 21:13 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huakang Biomedical Holdings Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.